SCHEMBL3862349

SCHEMBL3862349

Nc1nc2ccccc2c2c1ncn2CCCCNC(=O)c1cccc(C(=O)c2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 9/20 0.47
▸ HTR2A P28223 4/20 0.46
▸ ADRA1D P25100 2/20 0.46
▸ ADRA1A P35348 2/20 0.46
▸ KCNH2 Q12809 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ HRH2 P25021 1/20 0.46
▸ ADORA2A P29274 1/20 0.46
▸ NUDT1 P36639 1/20 0.46
▸ HTR2B P41595 1/20 0.46
▸ PDE4D Q08499 1/20 0.46
▸ TLR8 Q9NR97 1/20 0.41
▸ DRD2 P14416 4/20 0.41
▸ DRD3 P35462 4/20 0.41
▸ HTR1A P08908 3/20 0.40
▸ HTR2C P28335 2/20 0.40
▸ MAPK10 P53779 1/20 0.38
▸ MAPK14 Q16539 1/20 0.38
▸ KLKB1 P03952 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3867251 0.94 TLR7 (0.51) TLR7HTR2AADRA1DADRA1AKCNH2
SCHEMBL3862412 0.92 TLR7 (0.53) TLR7HTR2AADRA1DADRA1AKCNH2
SCHEMBL3863900 0.91 TLR7 (0.53) TLR7HTR2AADRA1DADRA1AKCNH2
SCHEMBL3866002 0.91 TLR7 (0.53) TLR7HTR2AADRA1DADRA1AKCNH2
SCHEMBL5748391 0.91 TLR7 (0.53) TLR7HTR2AADRA1DADRA1AKCNH2
SCHEMBL13937463 0.90 LMNA (0.47) TLR7HTR2AADRA1DADRA1AKCNH2
Hydrochloric Acid SCHEMBL3863251 0.90 TLR7 (0.52) TLR7HTR2AADRA1DADRA1AKCNH2
Hydrochloric Acid SCHEMBL3867142 0.90 TLR7 (0.51) TLR7HTR2AADRA1DADRA1AKCNH2
SCHEMBL3864117 0.89 LMNA (0.46) TLR7HTR2AADRA1DADRA1AKCNH2
SCHEMBL5749342 0.89 TLR7 (0.54) TLR7HTR2AADRA1DADRA1AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023722-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2009-01-22 — — US disclosed
US-20090023722-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2009-01-22 — — US disclosed
US-20090023722-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2009-01-22 — — US disclosed
US-7393859-B2 Amide substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-07-01 — — US disclosed
US-7393859-B2 Amide substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-07-01 — — US disclosed
US-7393859-B2 Amide substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-07-01 — — US disclosed
EP-1187613-B9 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2006-10-25 — — EP disclosed
EP-1187613-B1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2006-08-09 — — EP disclosed
US-20040229897-A1 Amide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-11-18 — — US disclosed
US-6756382-B2 SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS 3M INNOVATIVE PROPERTIES COMPANY 2004-06-29 — — US disclosed
US-20030144283-A1 Amide substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-07-31 — — US disclosed
US-6451810-B1 AID IN CYTOKINE BIOSYNTHESIS 3M INNOVATIVE PROPERTIES COMPANY 2002-09-17 — — US disclosed
EP-1187613-A4 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2002-07-24 — — EP disclosed
EP-1187613-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2002-03-20 — — EP disclosed
WO-2000076505-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229897-A1 Amide substituted imidazoquinolines IFNG, IRF3, EIF2AK2 TLR7 30/4885HTR2A 4537/4885ADRA1D 3704/4885
US-20090023722-A1 AMIDE SUBSTITUTED IMIDAZOQUINOLINES IFNG, IRF3, EIF2AK2 TLR7 30/4885HTR2A 4537/4885ADRA1D 3704/4885
US-20030144283-A1 Amide substituted imidazoquinolines IFNG, IRF3, EIF2AK2 TLR7 30/4885HTR2A 4537/4885ADRA1D 3704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback